{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:44Z","timestamp":1790776604016,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T00:00:00Z","timestamp":1401235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Targos Molecular Pathology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction.<\/jats:title><jats:p>We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods.<\/jats:title><jats:p>Patients received pertuzumab\/placebo at 840 mg in cycle 1 and 420 mg in subsequent cycles, and trastuzumab at 8 mg\/kg in cycle 1 and 6 mg\/kg in subsequent cycles; docetaxel was initiated at 75 mg\/m2. All study drugs were given intravenously, 3 times weekly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Docetaxel dose reductions below 75 mg\/m2 were more common in patients from Asia (47.0%) than other regions (13.4%); docetaxel dose escalations to 100 mg\/m2 were less frequent in Asia (2.4%) than other regions (18.7%). Rates of edema (26.1% and 5.4% for Asia and other regions, respectively), myalgia (42.3%, 14.7%), nail disorder (39.9%, 15.1%), febrile neutropenia (18.6%, 7.1%), upper respiratory tract infection (25.7%, 10.2%), decreased appetite (47.0%, 19.1%), and rash (44.3%, 22.0%) were at least twice as high in Asia as in other regions. Adverse events did not result in a reduction in the median number of study treatment cycles administered in patients from Asia. Efficacy analyses per region showed hazard ratios similar to those of the whole intention-to-treat (ITT) population for progression-free survival (ITT: 0.63; Asia: 0.68; other regions: 0.61) and overall survival (ITT: 0.66; Asia: 0.64; other regions: 0.66).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Despite a higher proportion of docetaxel dose reductions in patients from Asia, survival benefits were comparable between regions. The benefit-risk profile of pertuzumab, trastuzumab, and docetaxel supports this regimen as the first-line therapy for patients with HER2-positive metastatic breast cancer from all geographic regions.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0033","type":"journal-article","created":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T03:07:59Z","timestamp":1401332879000},"page":"693-701","source":"Crossref","is-referenced-by-count":59,"title":["Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA"],"prefix":"10.1093","volume":"19","author":[{"given":"Sandra M.","family":"Swain","sequence":"first","affiliation":[{"name":"Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valorie","family":"Chan","sequence":"additional","affiliation":[{"name":"Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miles","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Middlesex, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Knott","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Clark","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ross","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,5,28]]},"reference":[{"key":"2021122308570212500_B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2021122308570212500_B2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308570212500_B3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B4","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B8","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122308570212500_B10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122308570212500_B11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.597","article-title":"Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA","volume-title":"Poster presented at: 48th Annual Meeting of the American Society of Clinical Oncology","author":"Baselga","year":"2012"},{"key":"2021122308570212500_B12","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","article-title":"Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer","volume":"16","author":"Bruno","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B15","first-page":"1255","article-title":"The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance","volume":"6","author":"Hirth","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122308570212500_B16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.2000.18.11.2301","article-title":"Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol","volume":"18","author":"Yamamoto","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","article-title":"Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms","volume":"79","author":"Tran","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"2021122308570212500_B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","article-title":"Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver","volume":"8","author":"Shou","year":"1998","journal-title":"Pharmacogenetics"},{"key":"2021122308570212500_B19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0165-6147(89)90207-1","article-title":"Polymorphism of cytochrome P-450 in humans","volume":"10","author":"Guengerich","year":"1989","journal-title":"Trends Pharmacol Sci"},{"key":"2021122308570212500_B20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0009-9236(99)70037-8","article-title":"Population distribution and effects on drug metabolism of a genetic variant in the 5\u2032 promoter region of CYP3A4","volume":"66","author":"Ball","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2021122308570212500_B21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"key":"2021122308570212500_B22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"2021122308570212500_B23","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1124\/dmd.110.034140","article-title":"CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs","volume":"38","author":"Maekawa","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2021122308570212500_B24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drup.2008.03.002","article-title":"CYP450 pharmacogenetics for personalizing cancer therapy","volume":"11","author":"Van Schaik","year":"2008","journal-title":"Drug Resist Updat"},{"key":"2021122308570212500_B25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2005.11.036","article-title":"Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol","volume":"23","author":"Yamamoto","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","article-title":"Noninvasive tests of CYP3A enzymes","volume":"4","author":"Watkins","year":"1994","journal-title":"Pharmacogenetics"},{"key":"2021122308570212500_B27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/00912709922008182","article-title":"Differences in the urinary excretion of 6-beta-hydroxycortisol\/cortisol between Asian and Caucasian women","volume":"39","author":"Lin","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"2021122308570212500_B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.1993.155","article-title":"The influence of dose and ethnic origins on the pharmacokinetics of nifedipine","volume":"54","author":"Ahsan","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2021122308570212500_B29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer\u2014A retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2002","journal-title":"Radiother Oncol"},{"key":"2021122308570212500_B30","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ejca.2011.06.027","article-title":"Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer","volume":"47","author":"Han","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122308570212500_B31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/CAD.0000000000000016","article-title":"Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel","volume":"24","author":"Cort\u00e9s","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2021122308570212500_B32","first-page":"58","article-title":"Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs","volume":"56","author":"Royer","year":"1996","journal-title":"Cancer Res"},{"key":"2021122308570212500_B33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2021122308570212500_B34","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"key":"2021122308570212500_B35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"2021122308570212500_B36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"2021122308570212500_B37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Invest New Drugs"},{"key":"2021122308570212500_B38","first-page":"3480","article-title":"Optimizing the erythromycin breath test for use in cancer patients","volume":"6","author":"Rivory","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122308570212500_B39","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","article-title":"Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies","volume":"20","author":"Goh","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308570212500_B40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00280-004-0823-0","article-title":"Dexamethasone as a probe for docetaxel clearance","volume":"54","author":"Puisset","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308570212500_B41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003088-200140030-00001","article-title":"The erythromycin breath test for the prediction of drug clearance","volume":"40","author":"Rivory","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2021122308570212500_B42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1984.tb02504.x","article-title":"Accuracy and clinical utility of simplified tests of antipyrine metabolism","volume":"18","author":"Farrell","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"2021122308570212500_B43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/clpt.1992.140","article-title":"Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity","volume":"52","author":"Watkins","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"2021122308570212500_B44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3565(25)22834-8","article-title":"Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122308570212500_B45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122308570212500_B46","first-page":"2273","article-title":"Dose optimisation of carboplatin in adults","volume":"14","author":"Calvert","year":"1994","journal-title":"Anticancer Res"},{"key":"2021122308570212500_B47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/jnci\/djq117","article-title":"Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application","volume":"102","author":"Duff","year":"2010","journal-title":"J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2014-0033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/693\/41861909\/oncolo_19_7_693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/693\/41861909\/oncolo_19_7_693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:47:14Z","timestamp":1746247634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/7\/693\/6399352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,28]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,5,28]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0033","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7,1]]},"published":{"date-parts":[[2014,5,28]]}}}